Tools
Tools
Jamal-Hanjani, Mariam and Hackshaw, Alan and Ngai, Yenting and Shaw, Jacqueline and Dive, Caroline and Quezada, Sergio and Middleton, Gary and de Bruin, Elza and Le Quesne, John and Shafi, Seema and Falzon, Mary and Horswell, Stuart and Blackhall, Fiona and Khan, Iftekhar and Janes, Sam and Nicolson, Marianne and Lawrence, David and Forster, Martin and Fennell, Dean and Lee, Siow-Ming and Lester, Jason and Kerr, Keith and Muller, Salli and Iles, Natasha and Smith, Sean and Murugaesu, Nirupa and Mitter, Richard and Salm, Max and Stuart, Aengus and Matthews, Nik and Adams, Haydn and Ahmad, Tanya and Attanoos, Richard and Bennett, Jonathan and Birkbak, Nicolai Juul and Booton, Richard and Brady, Ged and Buchan, Keith and Capitano, Arrigo and Chetty, Mahendran and Cobbold, Mark and Crosbie, Philip and Davies, Helen and Denison, Alan and Djearman, Madhav and Goldman, Jacki and Haswell, Tom and Joseph, Leena and Kornaszewska, Malgorzata and Krebs, Matthew and Langman, Gerald and MacKenzie, Mairead and Millar, Joy and Morgan, Bruno and Naidu, Babu and Nonaka, Daisuke and Peggs, Karl and Pritchard, Catrin and Remmen, Hardy and Rowan, Andrew and Shah, Rajesh and Smith, Elaine and Summers, Yvonne and Taylor, Magali and Veeriah, Selvaraju and Waller, David and Wilcox, Ben and Wilcox, Maggie and Woolhouse, Ian and McGranahan, Nicholas and Swanton, Charles (2014) Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS biology, 12 (7). e1001906. ISSN 1545-7885.
|
Text (PDF file format)
http___www.plosbiology.org_article_fetchObject.action_uri=info_doi_10.1371_journal.pbio.pdf - Published Version Available under License Creative Commons Attribution. Download (717kB) | Preview |
Abstract
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.
| Item Type: | Article |
|---|---|
| Subjects: | QZ Pathology. Oncology WF Respiratory system. Respiratory medicine |
| Divisions: | Clinical Support > Pathology Clinical Support > Radiology Planned IP Care > Oncology and Clinical Haematology Planned IP Care > Thoracic Surgery |
| Related URLs: | |
| Depositing User: | Mrs Yolande Brookes |
| Date Deposited: | 30 Apr 2015 12:32 |
| Last Modified: | 30 Apr 2015 12:32 |
| URI: | http://www.repository.heartofengland.nhs.uk/id/eprint/891 |
Actions (login required)
 |
View Item |
